Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etilamfetamine SCHEMBL309802 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| Etilamfetamine SCHEMBL27754453 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| Etilamfetamine SCHEMBL16866783 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| Etilamfetamine SCHEMBL727383 | 0.98 | SIGMAR1 (0.96) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| Etilamfetamine SCHEMBL1650086 | 0.96 | SIGMAR1 (0.92) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL29059547 | 0.84 | SIGMAR1 (0.81) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL9134313 | 0.83 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL711506 | 0.83 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| N-Benzylamphetamine SCHEMBL2798189 | 0.83 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR | |
| N-Benzylamphetamine SCHEMBL2795222 | 0.83 | SIGMAR1 (1.00) | SIGMAR1CYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2189 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20240075043-A1 | IMMEDIATE AND CONTROLLED RELEASE APPETITE SUPPRESSANT COMPOSITIONS FOR WEIGHT LOSS | Red Mountain Med Spa, LLC (US) | 2024-03-07 | — | — | US | claimed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | claimed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | claimed |
| US-20220249505-A1 | APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF | RED MOUNTAIN HOLDINGS, LLC (US) | 2022-08-11 | — | — | US | claimed |
| US-20210275536-A1 | APPETITE SUPPRESSANT COMPOSITIONS AND METHODS THEREOF | RED MOUNTAIN HOLDINGS, LLC (US) | 2021-09-09 | — | — | US | claimed |
| US-20200060997-A1 | TARR Receptor Agonists for Sexual Dysfunction | JOHN MCCOY | 2020-02-27 | — | — | US | claimed |
| EP-3478363-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | Chemapotheca LLC (US) | 2019-05-08 | — | — | EP | claimed |
| EP-3366306-A2 | USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-08-29 | — | — | EP | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| EP-1165054-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | Pharmaquest Limited (BM) | 2002-01-02 | — | — | EP | claimed |
| JP-2001524960-A | — | — | 2001-12-04 | — | — | JP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6217904-B1 | MIXTURES; ADMINISTERING IN CYCLES | PHARMAQUEST LTD. (BM) | 2001-04-17 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000059481-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000059479-A1 | PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF METHYLPHENIDATE | PHARMAQUEST LTD. (BM) | 2000-10-12 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0977572-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LTD. (GB) | 2000-02-09 | — | — | EP | claimed |
| WO-1998047513-A1 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING EATING DISORDERS | MERCK SHARP & DOHME LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |